Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cervical cancer hearing

Executive Summary

FDA is expected to testify at Jan. 28 hearing of the House Government Reform/Human Resources Subcommittee on cervical cancer prevention and research. CDC, NCI and CMS have also been invited to the hearing, which will likely include discussion of the effectiveness of condoms in preventing transmission of human papillomavirus. Merck expects to file a BLA for an HPV vaccine in 2005 (1"The Pink Sheet" Dec. 22, 2003, p. 25)...

You may also be interested in...



HPV hearing

House Government Reform/Human Resources Subcommittee hearing Jan. 28 the "best strategies" to prevent human papillomavirus infection has been postponed until Feb. 5 (1"The Pink Sheet" Jan. 5, 2004, In Brief)...

Merck HPV Vaccine BLA Filing Expected In 2005, Four Years Before GSK

Merck's quadrivalent human papilloma virus vaccine could be approved by FDA up to four years before GlaxoSmithKline's HPV vaccine Cervarix is cleared for marketing in the U.S

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS043075

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel